TY - JOUR
T1 - Allergy History and Immunotherapy Response in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
AU - Alkhatib, Hosam H.
AU - Maroun, Christopher A.
AU - Guller, Meytal
AU - Cooper, Dylan J.
AU - Wu, Evan S.
AU - Eisele, David W.
AU - Fakhry, Carole
AU - Pardoll, Drew
AU - Seiwert, Tanguy Y.
AU - Zhu, Gangcai
AU - Mandal, Rajarsi
N1 - Publisher Copyright:
© 2023 American Academy of Otolaryngology–Head and Neck Surgery Foundation.
PY - 2024/3
Y1 - 2024/3
N2 - Objective: This study examines the association between patient-reported allergy history and immune checkpoint inhibition (ICI) response in patients with recurrent or metastatic head and neck squamous cell carcinoma (RMHNSCC). Study Design: Retrospective cohort study. Setting: Academic tertiary care hospital. Methods: Data were collected from the electronic medical records on baseline age, sex, allergy history, human papillomavirus status, T-stage, N-stage, smoking status, and survival for patients with and without an allergy history. The primary outcome was ICI response defined as complete or partial response by the RECIST criteria. Chi-square and logistic regression analyses were conducted to compare rates and odds of ICI response. Kaplan-Meier analyses were used to compare survival between groups. Results: Our study included 52 patients with an allergy history and 36 patients without an allergy history. The groups were similar in age, sex, HPV status, smoking status, and T- and N-stage. Patients with an allergy history (17/52, 32.1%) had a greater ICI response rate than patients without allergy history (4/36, 11.1%) (P =.02). After adjusting for HPV, patients with allergies had 3.93 (1.19-13.00) times increased odds of ICI response compared to patients without allergies. The median progression-free survival was 6.0 and 4.2 months for patients with and without an allergy history respectively (log-rank, P =.04). The median overall survival was 25.0 and 11.1 months for patients with and without an allergy history respectively (log-rank, P =.002). Conclusion: Patient-reported allergy history was associated with ICI response in patients with RMHNSCC, underscoring the potential clinical utility of allergy history in estimating ICI response.
AB - Objective: This study examines the association between patient-reported allergy history and immune checkpoint inhibition (ICI) response in patients with recurrent or metastatic head and neck squamous cell carcinoma (RMHNSCC). Study Design: Retrospective cohort study. Setting: Academic tertiary care hospital. Methods: Data were collected from the electronic medical records on baseline age, sex, allergy history, human papillomavirus status, T-stage, N-stage, smoking status, and survival for patients with and without an allergy history. The primary outcome was ICI response defined as complete or partial response by the RECIST criteria. Chi-square and logistic regression analyses were conducted to compare rates and odds of ICI response. Kaplan-Meier analyses were used to compare survival between groups. Results: Our study included 52 patients with an allergy history and 36 patients without an allergy history. The groups were similar in age, sex, HPV status, smoking status, and T- and N-stage. Patients with an allergy history (17/52, 32.1%) had a greater ICI response rate than patients without allergy history (4/36, 11.1%) (P =.02). After adjusting for HPV, patients with allergies had 3.93 (1.19-13.00) times increased odds of ICI response compared to patients without allergies. The median progression-free survival was 6.0 and 4.2 months for patients with and without an allergy history respectively (log-rank, P =.04). The median overall survival was 25.0 and 11.1 months for patients with and without an allergy history respectively (log-rank, P =.002). Conclusion: Patient-reported allergy history was associated with ICI response in patients with RMHNSCC, underscoring the potential clinical utility of allergy history in estimating ICI response.
KW - allergy
KW - head and neck cancer
KW - head and neck squamous cell carcinoma
KW - head and neck surgery
KW - immune checkpoint inhibition
KW - immunotherapy
KW - immunotherapy response
UR - http://www.scopus.com/inward/record.url?scp=85180195640&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85180195640&partnerID=8YFLogxK
U2 - 10.1002/ohn.582
DO - 10.1002/ohn.582
M3 - Article
C2 - 38123496
AN - SCOPUS:85180195640
SN - 0194-5998
VL - 170
SP - 828
EP - 836
JO - Otolaryngology - Head and Neck Surgery (United States)
JF - Otolaryngology - Head and Neck Surgery (United States)
IS - 3
ER -